ArticleJournal of experimental & clinical cancer research : CR2025

Tetrahydrobenzimidazole TMQ0153 targets OPA1 and restores drug sensitivity in AML via ROS-induced mitochondrial metabolic reprogramming.

Su Jung Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.